These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28638739)

  • 21. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.
    Li Q; Liu M; Wu M; Zhou X; Wang S; Hu Y; Wang Y; He Y; Zeng X; Chen J; Liu Q; Xiao D; Hu X; Liu W
    Oncol Lett; 2018 Apr; 15(4):5924-5932. PubMed ID: 29556312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-nonself discrimination and repertoire selection of human T cells differentiated in an HLA-semiallogeneic environment following bone marrow transplantation for severe combined immunodeficiency.
    Knobloch C; Goldmann SF; Friedrich W
    Eur J Immunol; 1991 Oct; 21(10):2479-87. PubMed ID: 1833204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection.
    Moris A; Teichgräber V; Gauthier L; Bühring HJ; Rammensee HG
    J Immunol; 2001 Apr; 166(8):4818-21. PubMed ID: 11290755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells.
    Yu XZ; Albert MH; Anasetti C
    J Immunol; 2006 Mar; 176(6):3383-90. PubMed ID: 16517706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
    Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
    Voss RH; Kuball J; Engel R; Guillaume P; Romero P; Huber C; Theobald M
    Immunol Res; 2006; 34(1):67-87. PubMed ID: 16720899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02⁺ patient with adult T-cell leukemia against a variety of HTLV-I-infected T-cells.
    Tanaka Y; Yamazaki R; Terasako-Saito K; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Sato M; Kimura S; Kikuchi M; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
    Immunol Lett; 2014; 158(1-2):120-5. PubMed ID: 24389072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
    Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
    Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens.
    Hess AD; Horwitz LR; Laulis MK; Fuchs E
    Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT).
    Bishara A; Amar A; Brautbar C; Condiotti R; Lazarovitz V; Nagler A
    Exp Hematol; 1995 Dec; 23(14):1667-75. PubMed ID: 8542963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective T-cell-receptor gene usage in allorecognition and graft-versus-host disease.
    Yamanaka K; Kwok WW; Mickelson EM; Masewicz S; Smith F; Nepom GT
    Transplantation; 1993 May; 55(5):1167-75. PubMed ID: 7684537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice.
    Firat H; Cochet M; Rohrlich PS; Garcia-Pons F; Darche S; Danos O; Lemonnier FA; Langlade-Demoyen P
    Int Immunol; 2002 Aug; 14(8):925-34. PubMed ID: 12147629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.
    Kawanishi Y; Passweg J; Drobyski WR; Rowlings P; Cook-Craig A; Casper J; Pietryga D; Garbrecht F; Camitta B; Horowitz M; Juckett M; Margolis D; Flomenberg N; Keever-Taylor CA
    Bone Marrow Transplant; 1997 Jun; 19(11):1069-77. PubMed ID: 9193748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.